Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308
Shaghayegh Nouruzi(University of British Columbia), Amina Zoubeidi(University of British Columbia)
Cited by 1
Related Papers
Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
|International Journal of Oncology|2014|158
Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD
|Cancer Research|2010|101
RETRACTED: Hsp27 regulates EGF/β‐catenin mediated epithelial to mesenchymal transition in prostate cancer
|International Journal of Cancer|2014|67